Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice

Calcified Tissue International

Volumn 88, Issue 6, 2011, Pages 511-520

  Ponnapakkam, Tulasi ^a,b   Katikaneni, R ^a,b   Miller, E ^c   Ponnapakkam, A ^c   Hirofumi, S ^d   Miyata, S ^d   Suva, L J ^e   Sakon, J ^f   Matsushita, O ^g   Gensure, R C ^a,b  

^a CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c OCHSNER CLINIC FOUNDATION   (United States)

^d KAGAWA UNIVERSITY   (Japan)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f UNIVERSITY OF ARKANSAS   (United States)

^g University Medical School   (Japan)

Author keywords

Bone mineral density; Collagen binding domain; Collagenase; Mice; Osteoporosis; Parathyroid hormone

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; COLLAGEN BINDING PROTEIN; COLLAGEN TYPE 1; COLLAGENASE; CYCLIC AMP; HYBRID PROTEIN; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN RECEPTOR; PARATHYROID HORMONE[1-33] COLLAGEN BINDING PROTEIN FUSION PROTEIN; PARATHYROID HORMONE[1-34]; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD FLOW; BONE; BONE DENSITY; CALCIUM BLOOD LEVEL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; SKIN; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANABOLIC AGENTS; ANIMALS; BACTERIAL PROTEINS; BONE AND BONES; COLLAGEN; COLLAGENASES; DRUG ADMINISTRATION SCHEDULE; FEMALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PARATHYROID HORMONE; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECOMBINANT FUSION PROTEINS; TIME FACTORS;

EID: 79959760740     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-011-9485-1     Document Type: Article

References (37)

1. National Osteoporosis Foundation (2009) About osteoporosis. Bone health basics. Why bone health is important. http://www.nof.org/aboutosteoporosis/ bonebasics/whybonehealth
2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465-475 (Pubitemid 46797130)
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333 (Pubitemid 34761611)
4. Miller SC, Jee WS (1979) The effect of dichloromethylene diphosphonate, a pyrophosphate analog, on bone and bone cell structure in the growing rat. Anat Rec 193:439-462
5. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246-1254 (Pubitemid 29268962)
6. Iwamoto J, Sato Y, Takeda T, Matsumoto H (2008) Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. Clin Interv Aging 3:483-489
7. Girotra M, Rubin MR, Bilezikian JP (2006) The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 7:113-121 (Pubitemid 46049523)
8. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441 (Pubitemid 32402100)
9. Poole KE, Reeve J (2005) Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol 5:612-617 (Pubitemid 41614461)
10. Miller PD (2008) Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep 6:12-16
11. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M (2004) Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426-438 (Pubitemid 38998935)
12. Vahle JL, Zuehlke U, Schmidt A, Westmore M, Chen P, Sato M (2008) Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res 23:2033-2039
13. Harper KD, Krege JH, Marcus R, Mitlak BH (2007) Osteosarcoma and teriparatide? J Bone Miner Res 22:334
14. Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA (1041) Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 21:1041-1045
15. Bilezikian JP (2008) Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep 6:24-30
16. Kostenuik PJ, Ferrari S, Pierroz D, Bouxsein M, Morony S, Warmington KS, Adamu S, Geng Z, Grisanti M, Shalhoub V, Martin S, Biddlecome G, Shimamoto G, Boone T, Shen V, Lacey D (2007) Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone. J Bone Miner Res 22:1534-1547 (Pubitemid 351229324)
17. Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, Saxton JM, Kronenberg HM, Baron R, Schipani E (2001) Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 107:277-286 (Pubitemid 32157960)
18. Gensure RC, Gardella TJ, Juppner H (2001) Multiple sites of contact between the carboxyl-terminal binding domain of PTHrP-(1-36) analogs and the amino-terminal extracellular domain of the PTH/PTHrP receptor identified by photoaffinity cross-linking. J Biol Chem 276:28650-28658
19. Wittelsberger A, Corich M, Thomas BE, Lee BK, Barazza A, Czodrowski P, Mierke DF, Chorev M, Rosenblatt M (2006) The mid-region of parathyroid hormone (1-34) serves as a functional docking domain in receptor activation. Biochemistry 45:2027-2034 (Pubitemid 43271302)
20. Jonsson KB, John MR, Gensure RC, Gardella TJ, Juppner H (2001) Tuberoinfundibular peptide 39 binds to the parathyroid hormone (PTH)/PTH-related peptide receptor, but functions as an antagonist. Endocrinology 142:704-709 (Pubitemid 32222420)
21. Matsushita O, Jung CM, Minami J, Katayama S, Nishi N, Okabe A (1998) A study of the collagen-binding domain of a 116-kDa Clostridium histolyticum collagenase. J Biol Chem 273:3643-3648 (Pubitemid 28109790)
22. Toyoshima T, Matsushita O, Minami J, Nishi N, Okabe A, Itano T (2001) Collagen-binding domain of a Clostridium histolyticum collagenase exhibits a broad substrate spectrum both in-vitro and in-vivo. Connect Tissue Res 42:281-290 (Pubitemid 33138550)
23. Matsushita O, Koide T, Kobayashi R, Nagata K, Okabe A (2001) Substrate recognition by the collagen-binding domain of Clostridium histolyticum class I collagenase. J Biol Chem 276:8761-8770
24. Philominathan ST, Koide T, Hamada K, Yasui H, Seifert S, Matsushita O, Sakon J (2009) Unidirectional binding of clostridial collagenase to triple helical substrates. J Biol Chem 284:10868-10876
25. Wilson JJ, Matsushita O, Okabe A, Sakon J (2003) A bacterial collagen-binding domain with novel calcium-binding motif controls domain orientation. EMBO J 22:1743-1752 (Pubitemid 36460131)
26. Bergwitz C, Jusseaume SA, Luck MD, Juppner H, Gardella TJ (1997) Residues in the membrane-spanning and extracellular loop regions of the parathyroid hormone (PTH)-2 receptor determine signaling selectivity for PTH and PTH-related peptide. J Biol Chem 272:28861-28868 (Pubitemid 27498166)
27. Katikaneni R, Ponnapakkam A, Miller E, Ponnapakkam T, Gensure RC (2009) A new technique for precisely and accurately measuring lumbar spine bone mineral density in mice using clinical dual energy X-ray absorptiometry (DXA). Toxicol Mech Methods 19:225-231
28. Tamai E, Ishida T, Miyata S, Matsushita O, Suda H, Kobayashi S, Sonobe H, Okabe A (2003) Accumulation of Clostridium perfringens epsilon-toxin in the mouse kidney and its possible biological significance. Infect Immun 71:5371-5375 (Pubitemid 37070786)
29. Shimamoto S, Tamai E, Matsushita O, Minami J, Okabe A, Miyata S (2005) Changes in ganglioside content affect the binding of Clostridium perfringens epsilon-toxin to detergent-resistant membranes of Madin-Darby canine kidney cells. Microbiol Immunol 49:245-253
30. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406 (Pubitemid 38094536)
31. Hildebrand T, Laib A, Muller R, Dequeker J, Ruegsegger P (1999) Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 14:1167-1174 (Pubitemid 29314060)
32. Bagi CM, Hanson N, Andresen C, Pero R, Lariviere R, Turner CH, Laib A (2006) The use of micro-CT to evaluate cortical bone geometry and strength in nude rats: correlation with mechanical testing, pQCT and DXA. Bone 38:136-144 (Pubitemid 43006084)
33. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905-916
34. Goldhaber P, Roth SI, Cirulis G (1964) the effect of parathyroid and other human tumors and tissues on bone resorption in tissue culture. Cancer Res 24:254-259
35. Gensure RC, Gardella TJ, Juppner H (2005) Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun 328:666-678 (Pubitemid 40208304)
36. Barbehenn EK, Lurie P, Wolfe SM (2001) Osteosarcoma risk in rats using PTH 1-34. Trends Endocrinol Metab 12:383
37. Iida-Klein A, Hughes C, Lu SS, Moreno A, Shen V, Dempster DW, Cosman F, Lindsay R (2006) Effects of cyclic versus daily hPTH(1-34) regimens on bone strength in association with BMD, biochemical markers, and bone structure in mice. J Bone Miner Res 21:274-282 (Pubitemid 43265293)